CN101912497B - Medicament for treating bone fracture - Google Patents
Medicament for treating bone fracture Download PDFInfo
- Publication number
- CN101912497B CN101912497B CN2010102627565A CN201010262756A CN101912497B CN 101912497 B CN101912497 B CN 101912497B CN 2010102627565 A CN2010102627565 A CN 2010102627565A CN 201010262756 A CN201010262756 A CN 201010262756A CN 101912497 B CN101912497 B CN 101912497B
- Authority
- CN
- China
- Prior art keywords
- radix
- fine powder
- medicine
- medicament
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicament for treating bone fracture, which comprises the following active ingredients by weight: 8 to 10g of Chinese angelica, 14 to 16g of keel, 8 to 10g of szechuan lovage rhizome, 8 to 10g of red flower, 9 to 11g of Chinese pyrola herb, 8 to 10g of rhubarb, 14 to 16g of salvia miltiorrhiza, 14 to 16g of dipsacus asperoides, 8 to 10g of campanumaea pilosula, 0.8 to 1.0g of native copper, 2 to 4g of ground beeltle, 0.8 to 1.2g of dragon's blood, 4.0 to 5.0g of pseudoginseng root, 0.08 to 0.12g of borneol and 1.2 to 1.8g of prepared frankincense and myrrh. The medicament is prepared by the following steps of: grinding the native copper, ground beeltle, Chinese angelica, prepared frankincense and myrrh, dragon's blood, pseudoginseng root, borneol and szechuan lovage rhizome into fine powder, and screening; soaking keel, red flower, Chinese pyrola herb, rhubarb, salvia miltiorrhiza, dipsacus asperoides and campanumaea pilosula with warm water, decocting, filtering the decoction, concentrating the filter liquor into extract and drying to prepare fine powder; and uniformly mixing the fine powder and taking water as an adhesive to prepare pills. The medicament for treating the bone fracture has the advantages of capacities of reducing swelling and easing pain, accelerating fracture healing and eliminating stasis and stopping pain, no toxic or side effect, exact curative effect and safe and reliable clinical application.
Description
Technical field
The present invention relates to the medicine of a kind of Chinese Traditional Medicines, particularly a kind of set a broken bone.It is a kind of oral administered compound Chinese patent medicine, is used for set a broken bone.
Background technology
Bone injury means a kind of disease that causes sclerotin partially or even wholly to rupture owing to reasons such as wound or pathology.Its main clinical manifestation is: fractures has limitation pain and tenderness, local swelling and ecchymosis occurs, and limb function is partially or completely lost, and the completeness sclerotin still cacomelia and abnormal movement can occur.Medical circle is through using the continuous practice and the research of modernized scientific method and theory of integrated Chinese and western medicine in recent years, developed the medicine that many infection, reducing swelling and alleviating pain, promotion heal, like the aspirin of Western medicine etc.; The JIEGU QILI PIAN of Chinese medicine etc.Though these medicines have certain effect to set a broken bone, because these medicines are to digestive system, hepatic and renal function etc. have toxic and side effects in various degree, thus influence and limited the clinical application range and the therapeutic effect of these medicines.
Summary of the invention
The object of the present invention is to provide a kind of medicine of set a broken bone, it can overcome the deficiency of prior art, and reducing swelling and alleviating pain promotes union of fracture effectively, eliminating stasis to stop pain, and its determined curative effect has no side effect again.
The active component of medicine of the present invention is made up of following component and weight proportion thereof.Its concrete component is calculated by weight as follows:
Radix Angelicae Sinensis 8-10g, Os Draconis 14-16g, Rhizoma Chuanxiong 8-10g, Flos Carthami 8-10g; Herba Pyrolae 9-11g, Radix Et Rhizoma Rhei 8-10g, Radix Salviae Miltiorrhizae 14-16g, Radix Dipsaci 14-16g; Radix Codonopsis 8-10g, Pyritum 0.8-1.0g, Eupolyphaga Seu Steleophaga 2-4g, Sanguis Draxonis 0.8-1.2g; Radix Notoginseng 4.0-5.0g, Borneolum Syntheticum 0.08-0.12g, the system breast does not have each 1.2-1.8g.
Take by weighing raw material by above-mentioned formula ratio, with Pyritum, Eupolyphaga Seu Steleophaga, Radix Angelicae Sinensis, system breast do not have, Sanguis Draxonis, Radix Notoginseng, Borneolum Syntheticum, Rhizoma Chuanxiong be developed into fine powder, sieve; With Os Draconis, Flos Carthami, Herba Pyrolae, Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae, Radix Dipsaci, Radix Codonopsis water temperature soak, decoction, decocting liquid filter, filtrating is condensed into extractum, drying is processed fine powder, and with above-mentioned fine powder mix homogeneously, be that binding agent is processed pill with water.
Motherland's medical science is thought, damages venation behind the exogenous injury, and QI-blood flowing out of meridian causes qi depression to blood stasis, so card is seen pain and swelling, limb can not be lifted.The blood stasis of blood of not living then can not be gone, and the stasis of blood does not go then that bone can not connect.In medicine of the present invention, Flos Carthami has to invigorate blood circulation to be moisturized, and the effect of eliminating stasis to stop pain is the monarch of this magistral medicines.Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Eupolyphaga Seu Steleophaga, Sanguis Draxonis etc. have enrich blood invigorate blood circulation, reducing swelling and alleviating pain, promoting tissue regeneration by removing blood stasis effect, be the minister of this magistral medicines.Assistant is with Radix Dipsaci, Pyritum, Os Draconis, Radix Salviae Miltiorrhizae, Radix Codonopsis the liver and the kidney tonifying, dissipating blood stasis collateral dredging, the article of reunion of fractured tendons and bones.Do not have with Radix Et Rhizoma Rhei, Radix Notoginseng, Borneolum Syntheticum, system breast that removing blood stasis leads to blood, powder for dispersing blood stasis is become makes.Above-mentioned all medicines are collaborative, have removing blood stasis and activating blood flow, reducing swelling and alleviating pain, dredge the meridian passage, promoting tissue regeneration by removing blood stasis, the liver and the kidney tonifying, the effect of reunion of fractured tendons and bones.
The present invention adopts technique scheme, from stability, pharmacodynamics, toxicology test and clinical observation on the therapeutic effect that this medicine is carried out, can find out; Pharmaceutical properties of the present invention is stable; Has analgesic activity preferably, good antiinflammatory action, stronger function of promoting blood circulation to disperse blood clots; Can promote union of fracture effectively, and toxic and side effects is little, clinical practice is safe and reliable, and determined curative effect is a kind of treatment Chinese patent medicine preferably of fracturing.
Description of drawings
Accompanying drawing is a kind of process chart of method for preparing of medicine of set a broken bone.
The specific embodiment
Describe the specific embodiment of the present invention in detail below in conjunction with embodiment
Embodiment 1
Take by weighing raw material by formula ratio, Radix Angelicae Sinensis 9g, Os Draconis 15g, Rhizoma Chuanxiong 9g, Flos Carthami 9g, Herba Pyrolae 10g, Radix Et Rhizoma Rhei 9g, Radix Salviae Miltiorrhizae 15g, Radix Dipsaci 15g, Radix Codonopsis 9g, calcine Pyritum 0.9g, Eupolyphaga Seu Steleophaga 3g, Sanguis Draxonis 0.8g, Radix Notoginseng 4.5g, Borneolum Syntheticum 0.1g, the system breast does not have each 1.5g.And adopt following method for preparing: earlier will the above-mentioned calcine Pyritum that takes by weighing, Eupolyphaga Seu Steleophaga, Radix Angelicae Sinensis, system breast do not have, Sanguis Draxonis, Radix Notoginseng, Borneolum Syntheticum, Rhizoma Chuanxiong raw medicinal material, pulverize separately is processed fine powder, then mix, and the medical sieve of mistake, subsequent use; Again with the Radix Salviae Miltiorrhizae that takes by weighing, Flos Carthami, Os Draconis, Radix Et Rhizoma Rhei, Radix Dipsaci, Herba Pyrolae, Radix Codonopsis raw medicinal material, place container and add the water of 10 times of amounts of medical material weight, warm macerating 0.5h decocts 2.5h; Leach decocting liquid, the water that adds 10 times of amounts again carries out decocting the second time 1.5h, and the elimination medicinal residues get decocting liquid for the second time; Chinese crude drug filtering residue extruding obtains squeezed fluid and merges with decocting liquid for the second time, and medicinal residues emit, and will filtrate in evaporating dish behind the water bath method; Dry 3h under 105 ℃ of temperature moves in the exsiccator again, cooling 30min; Measure in the time of between 60 ℃-65 ℃ of temperature, filtrating is condensed to the extractum of relative density 1.30-1.32, with this extract dry, pulverize, process fine powder; With above-mentioned two kinds of fine powder mix homogeneously, be binding agent with water, process 1000 of watered pill, be dried to dried ball, packing gets final product.Every is equivalent to crude drug 0.15g.Instructions of taking and consumption: oral, every day 3 times, each 20.
Above-mentioned all raw medicinal materials are all on sale on market, are prone to purchase.
Embodiment 2
Take by weighing raw material by formula ratio, Radix Angelicae Sinensis 10g, Os Draconis 16g, Rhizoma Chuanxiong 10g, Flos Carthami 10g, Herba Pyrolae 11g; Radix Et Rhizoma Rhei 10g, Radix Salviae Miltiorrhizae 16g, Radix Dipsaci 16g, Radix Codonopsis 10g, calcine Pyritum 0.8g; Eupolyphaga Seu Steleophaga 4g, Sanguis Draxonis 1.2g, Radix Notoginseng 5g, Borneolum Syntheticum 0.12g, the system breast does not have each 1.8g.Other is all with embodiment 1.
Embodiment 3
Take by weighing raw material by formula ratio, Radix Angelicae Sinensis 8g, Os Draconis 14g, Rhizoma Chuanxiong 8g, Flos Carthami 8g, Herba Pyrolae 9g, Radix Et Rhizoma Rhei 8g, Radix Salviae Miltiorrhizae 14g, Radix Dipsaci 14g, Radix Codonopsis 8g, calcine Pyritum 0.8g, Eupolyphaga Seu Steleophaga 2g, Sanguis Draxonis 0.8g, Radix Notoginseng 4g, Borneolum Syntheticum 0.08g, the system breast does not have each 1.2g.Other is all with embodiment 1.
Medicine is differentiated: get medicine of the present invention, put microscopically and observe: phloem parenchyma cell spindle wall is slightly thick, and there is imperceptible oblique cross lamination on the surface, visible sometimes poor tabula.Faint yellow or the light yellow of irregular agglomerate is formed by colourless oil droplet or the gathering of faint yellow oil droplet fine particle, adds oil red test solution oil droplet and takes on a red color.Irregular agglomerate is light yellow, contains little yellow oil droplet in the fragment cave, adds oil red test solution oil droplet and takes on a red color.
Through health examination, should meet each item regulation (an appendix I of Chinese Pharmacopoeia version in 2005 A) relevant under the pill item.
Test Example
1, pharmacodynamics test:
Test objective: observe medicine of the present invention and whether have analgesia, detumescence, promotion union of fracture effect, and carry out the pharmacodynamics contrast, for clinical application provides experimental basis with JIEGU QILI PIAN or aspirin tablet.
Before the test, trial drug of the present invention and JIEGU QILI PIAN and aspirin tablet are ground respectively, be mixed with the suspension of desired concn respectively with 3%CMC-Na solution, supply the laboratory animal gastric infusion.
<1>Influence to the mouse writhing reaction: utilize 40 of Kunming mouses, body weight 18-22g, ♀ ♂ dual-purpose is divided into 4 groups at random, sets up negative control distilled water group (isometric(al)) separately, positive aspirin matched group (0.2gkg
-1), trial drug ball high dose group (0.2gkg of the present invention
-1), low dose group (1.0gkg
-1, press 0.2mL10g
-1) every day 1 gastric infusion, successive administration 3d injects 0.3% acetum 0.2mlkg in last administration 30min pneumoretroperitoneum
-1, observing and turn round the body number of times in every mice 30min, the result sees table 1.Compare with negative control distilled water group, medicine of the present invention can obviously reduce the mouse writhing number of times due to the acetic acid.
< 2>the mice thermostimulation is caused the influence of reacting bitterly and select 18～22g Kunming kind ♀ mice for use, measure and screen each Mus pain threshold.To screen qualified mice and be divided into 4 groups at random, 10 every group, repeat to measure two subnormal threshold of pain meansigma methodss as this Mus administration before pain threshold.Adopt above-mentioned < 1>identical packet mode and identical gastric infusion amount, successive administration 3d, 15min after the last administration; 30min, 60min surveys pain threshold respectively again on constant temperature analgesia analyzer; Still reactionless like 60s, its pain threshold calculates with 60s, and the result sees table 2.Compare with negative control distilled water group, medicine of the present invention can obviously improve the pain threshold of mice.
< 3>xylol causes the influence of mice ear: by the scorching method of caused by dimethylbenzene xylene, get 40 of ♂ mices, be divided into 4 groups at random; With above-mentioned < 1>item, successive administration 7d, 1h after the last administration; Mouse right ear evenly is coated with xylene 30 μ L and causes inflammation, puts to death mice after being coated with proinflammatory agent 30min, gets the auricle at the corresponding position of bilateral ear; Weigh, the difference of left and right sides auricle weight is the swelling degree.The result sees table 3.Compare with negative control distilled water group, medicine of the present invention can obviously suppress xylene induced mice ear swelling.
< 4>to the bullate influence of rat granuloma: get 40 of ♂ rat body weight 150-190g, be divided into 4 groups at random, and getting rat is undergone surgery, from performing the operation the same day by cotton pellet method; With above-mentioned < 1>item, successive administration 14d, 1d after the last administration takes out cotton balls in the rat body; Reject fat, weigh, dry under 60 ℃ of conditions, weigh again; Deduct the former weight of cotton balls, promptly get granuloma weight in wet base and dry weight, the result sees table 4.Compare with negative control group, medicine of the present invention can obviously alleviate the bullate hypertrophy of rat granuloma.
< 5>to the influence of rabbit experiment property union of fracture effect: get 40 of the healthy Japanese white big ear rabbits of body weight 1.5～2.5kg, ♀ ♂ dual-purpose.Perform the operation under the anesthesia, cause bilateral radius stage casing 4mm complete collyriculum, postoperative intramuscular injection anti-infectives.After the modeling, animal is divided into 4 groups at random, < 1>item method, successive administration is fed under identical conditions, and observes following index in the administration different time with above-mentioned.1. the X sheet is observed: 10d after the administration, and 20d, 30d takes the photograph the X-ray sheet in 50KV, GE500MA, 0.03S, 70cm condition, adopts Shanghai orthopaedics institute X sheet evaluation criterion to each sample evaluation, and the result sees table 5.Behind the drug administration group administration 10d of the present invention, have significantly that the X line changes, the fracture end trend is fuzzy, and slight periosteal reaction is arranged, and indivedual BIAO and BEN have callus formation in a small amount, and that the BIAO and BEN of matched group shows as fracture end is fuzzy, slight periosteal reaction, no callus it is thus clear that.Drug administration group periosteal reaction of the present invention on the 20th and callus formation are more obvious; The 30th day, 50% BIAO and BEN demonstration fracture edge complete obiteration is arranged in the high dose administration group, callus density and cortical bone are approaching; Basically reach knitting, and matched group does not all reach this degree.2. histological observation: treating excess syndrome test the long segment mark of rabbit defect 2cm this, after drug treating, section with HE dyeing, is observed callus and is changed, the result sees table 6.Defect is the area of new bone girder, and is woven into net, and the newborn bone trabecula of part is arranged according to the major axis of bone again, and close proximity, makes original gap become tiny crack, forms cortical bone wrinkle shape, and the bone cavity passage appears in central part.And the union of fracture degree of matched group is considerably slower than the administration group.
< 6>to the influence of hemorheology of rat: get 40 of SD rats, ♀ ♂ dual-purpose is divided into 4 groups at random, with above-mentioned < 1 >, behind the successive administration 15d, measures the blood flow variate, and the result sees table 7.Compare with negative control group, can reduce plasma viscosity, can improve hemorheological property.
Pharmacodynamics test shows:
(1) medicine of the present invention has analgesic activity preferably, and it can improve mice thermostimulation is caused the pain threshold that pain is reacted, and the time that ability significant prolongation acetic acid induced mice writhing response occurs, compares P＜0.05～0.01 with negative control group.
(2) good antiinflammatory action is arranged, medicine of the present invention can significantly suppress xylene induced mice auricle swelling degree, can obviously alleviate the bullate weight of rat granuloma, compares P＜0.05～0.01 with negative control group.
(3) stronger function of promoting blood circulation to disperse blood clots is arranged, medicine of the present invention has obvious reduction plasma viscosity, can improve hemorheological property, has function of promoting blood circulation to disperse blood clots.Compare P＜0.01 with negative control group, and be superior to positive controls.
(4) the healing effect that promotes fracture is arranged, medicine of the present invention can promote the osteocyte growth, increases bone trabecula, accelerates the formation of osseous callus, obviously promotes the bony union of rabbit experiment property fracture, and effect and JIEGU QILI PIAN are approaching.
(5) toxic and side effects is little, and the mice maximum dosage-feeding is 10gkg
-1, be 90 times of people's usual amounts, so clinical practice is safe and reliable.
2, toxicology test:
<1>Acute toxicity test: get 30 of body weight 18～22g mices, ♀ ♂ dual-purpose is divided into 2 groups at random, i.e. administration group and matched group, and the administration group is pressed 0.2ml (10g) with drug suspension of the present invention
-1The body weight gastric infusion, morning and afternoon each 1 time, matched group is irritated the isometric 0.3%CMC-Na solution of stomach, successive administration 7d, the observation experiment animal, administration group mice all survives.Above-mentioned 2 treated animals are at equal Non Apparent Abnormalities in aspect such as the form of main organs such as drinking-water, feces, hair color, body weight and the heart, liver, spleen, lung, kidney, size, smoothnesss.2 treated animal body weight are seen table 8.
Show by above-mentioned test: owing to adopt medicine of the present invention can not do LD50 through trial test; Can only do a day maximum tolerated dose; Its experimental result is 20g/kg (containing crude drug); Behave 133 times (people's consumption per day is 9g, and body weight is by 60kg) of daily consumption, after the administration in 7 days 2 treated animals do not see death and other abnormal responses.Experimental result shows that medicine of the present invention does not have tangible acute toxicity effect to mice.
< 2>chronic toxicity test:
Bolus of drug of the present invention is ground into fine powder crosses 80 mesh sieves, process the suspension that contains crude drug 0.20g/ml and 0.05g/ml, rat (Wister kind), body weight 100-122g are carried out chronic toxicity test with this medicinal liquid with the 0.5%CMC-Na aqueous solution.If ((15g/kg is equivalent to 100 times of human dosage approximately), low dose group (4.5g/kg is equivalent to 30 times of human dosage approximately) and blank group are to call high dose administration group, low dosage administration group and matched group in the following text for high dose group.To 1 time/d of high and low dose administration group timing administration, the blank group regularly gives 0.5%CMC-Na aqueous solution 2mg/100g body weight every day, freely drinks water the standard of freely ingesting cubed feed.At administration 90d; High dose group, low dose group and blank group are respectively got half laboratory animal and are put to death; Do conventional hematology's standard detection and blood parameters and detect, and core, liver,kidney,spleen, lung, brain make organ coefficient and measure macroscopy and check pathological section; With after all the other 2 weeks of animal drug withdrawal, do above-mentioned same inspection again, testing result is following:
1. ordinary circumstance: high and low dose administration group and matched group relatively, experimental session 3 treated animal hair colors are clean all the time, extremity, eye and pupil are normal, can freely ingest, and drink water, feces is normal in pelletized form, the 2nd week after the drug withdrawal, the equal no abnormality seen of all laboratory animals.2. table 9 is seen in the influence of body weight; Table 10 is seen in influence to routine urinalysis; Table 11 is seen in influence to hematological indices; Table 12 is seen in influence to hematology's biochemical indicator; Table 13 is seen in influence to each organ coefficient.
Above-mentioned chronic toxicity test shows; Utilizing medicine medicinal liquid of the present invention to carry out the high and low dose group observes through the 90d long term toxicity test; 1 time/d of gastric infusion, animal ordinary circumstance, body weight, hematology detect with the blank group and compare there was no significant difference during administration; Administration 90d and respectively laboratory animal is put to death after 2 weeks of drug withdrawal after, the heart, liver, spleen, lung, kidney, the brain of each treated animal carried out perusal and check pathological section, all no abnormality seen.Above-mentioned test shows that the medicinal liquid of medicine of the present invention does not see that in to the rat chronic toxicity test toxic reaction occurs, and does not also find the after effect that is caused by cumulative toxicity in 2 weeks of drug withdrawal.Therefore, medicine of the present invention has higher-security.
3, clinical observation on the therapeutic effect:
Adopt medicine of the present invention observation of curative effect 217 routine radius far-end fracture persons in clinical; Consultation time is within 24h after the wound, and the reduction of warp application fracture of upper limb reset device reaches dissection or near anatomical position, resets; After clamping plate are fixing; The method of employing random packet is divided into observed drug group of the present invention (hereinafter to be referred as observation group) and JIEGU QILI PIAN matched group (hereinafter to be referred as matched group) is treated and clinical observation, and two groups have obvious comparability.Carry out oral relative medicine more respectively after 6 weeks; Observe period in a medicine swelling, pain, X ray examination growth of spur situation and toxic and side effects, and analyze contrast and sum up, observation group and matched group have tangible comparability; Above-mentioned two groups of therapeutic outcomes show; At reducing swelling and alleviating pain, promotion union of fracture aspects, the therapeutic effect of observation group obviously is superior to matched group, and has no side effect.See table 14 and table 15 for details.
The influence of table 1 Dichlorodiphenyl Acetate induced mice writhing response
Annotate: compare * P＜0.05 with said negative control group
The influence of table 2 pair thermostimulation induced mice pain threshold
Annotate: compare * P＜0.05 with said negative control group
Table 3 xylol causes the influence of mice ear
Annotate: compare * P＜0.05 with said negative control group
The bullate influence of table 4 pair rat granuloma (.x ± s)
Annotate: compare * P＜0.05 with said negative control group
Table 5 couple union of fracture x-ray observation result
Annotate: "+" expression X sheet shows the union of fracture degree
The table 6 pair histological influence of rabbit fracture model callus
The influence of table 7 pair hemorheology of rat
Annotate: compare * P＜0.05 with negative control group
Table 8 acute toxicity testing is to the influence of mice body weight
Table 9 chronic toxicity test is to the influence of rat body weight
Table 10 chronic toxicity test is to the influence of rat routine urinalysis
The influence of index is learned in table 11 chronic toxicity test to rat blood
Table 12 chronic toxicity test is to the influence of rat blood biochemical indicator
Table 13 chronic toxicity test is to the influence of each organ coefficient of rat
Table 14 3,4,5, the 6 all X ray examination growth of spur situation of taking medicine
Annotate: through χ
2Check two groups of relatively P＜0.05
Pain and swelling disappearance and clinical union of bone time after table 15 is taken medicine (my god)
Annotate: through χ
2Check two groups of relatively P＜0.05.
Claims (1)
1. the medicine of a set a broken bone is characterized in that, fills a prescription to be Radix Angelicae Sinensis 8-10g, Os Draconis 14-16g; Rhizoma Chuanxiong 8-10g, Flos Carthami 8-10g, Herba Pyrolae 9-11g, Radix Et Rhizoma Rhei 8-10g, Radix Salviae Miltiorrhizae 14-16g; Radix Dipsaci 14-16g, Radix Codonopsis 8-10g, Pyritum 0.8-1.0g, Eupolyphaga Seu Steleophaga 2-4g, Sanguis Draxonis 0.8-1.2g; Radix Notoginseng 4-5g, Borneolum Syntheticum 0.08-0.12g, the system breast does not have each 1.2-1.8g
Press formula ratio weighting raw materials material, with Pyritum, Eupolyphaga Seu Steleophaga, Radix Angelicae Sinensis, system breast do not have, Sanguis Draxonis, Radix Notoginseng, Borneolum Syntheticum, Rhizoma Chuanxiong be developed into fine powder, and be subsequent use; Os Draconis, Flos Carthami, Herba Pyrolae, Radix Et Rhizoma Rhei, Radix Salviae Miltiorrhizae, Radix Dipsaci, Radix Codonopsis are soaked 0.5h with the water temperature of 10 times of amounts of medical material weight, decoct 2.5h, leach decocting liquid, the water of 10 times of amounts of reuse decocts 1.5h for the second time; The elimination medicinal residues, the secondary decocting liquid, and with the medical material filtering residue push squeezed fluid and preceding twice decocting liquid merging; Water bath method then, dry 3h under 150 ℃ of temperature, cooling 30min; Be condensed into the extractum of relative density 1.30-1.32, dry again, process fine powder; Subsequent use, with above-mentioned two kinds of fine powder uniform mixing, be that binding agent is processed pill with water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102627565A CN101912497B (en) | 2010-08-26 | 2010-08-26 | Medicament for treating bone fracture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102627565A CN101912497B (en) | 2010-08-26 | 2010-08-26 | Medicament for treating bone fracture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101912497A CN101912497A (en) | 2010-12-15 |
| CN101912497B true CN101912497B (en) | 2012-04-25 |
Family
ID=43320244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102627565A Expired - Fee Related CN101912497B (en) | 2010-08-26 | 2010-08-26 | Medicament for treating bone fracture |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101912497B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103463351B (en) * | 2013-09-10 | 2015-07-29 | 胡川洋 | A kind of Chinese medicine for the treatment of femur head necrosis |
-
2010
- 2010-08-26 CN CN2010102627565A patent/CN101912497B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 段西峰，等.散瘀止痛接骨丸治疗骨折的临床疗效观察.《中成药》.2003,第25卷(第8期),第684-686页. * |
| 王新春,等.散瘀止痛接骨丸药效学及急性毒性实验.《中成药》.2003,第25卷(第5期),第393-396页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101912497A (en) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN101849979B (en) | Chinese medicinal composition granules and preparation method thereof | |
| CN103239542B (en) | Medicament for treating gouty arthritis prepared from traditional Chinese medicines and preparation method thereof | |
| CN105327069A (en) | Formulation, preparation method and application of liver soothing traditional Chinese herbal medicine composition | |
| CN101380359B (en) | Bone-building capsules and preparation method thereof | |
| CN101912497B (en) | Medicament for treating bone fracture | |
| CN103721130B (en) | A kind of Chinese medicine composition for treating gout anti-trioxypurine | |
| CN1256120C (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN110384787A (en) | A kind of Chinese medicine composition and preparation method thereof for treating allergic rhinitis | |
| CN104043042A (en) | Traditional Chinese medicine composition for treating hepatic calculus | |
| CN103550688A (en) | Traditional Chinese medicine (TCM) composition for treating palpitation | |
| CN103655771B (en) | Treat Chinese medicine preparation of skin ulcer and preparation method thereof | |
| CN101406556B (en) | Chinese medicine preparation for treating acute prostatitis, prostatic hyperplasia and preparation method thereof | |
| CN110433226A (en) | A kind of Chinese medicine composition and preparation and its preparation method and application for treating urarthritis or hyperuricemia | |
| CN110237161A (en) | Drug and its preparation method and application for treating menopausal syndrome | |
| CN103800736A (en) | Pharmaceutical composition for treating hypertensive nephrosclerosis and application of pharmaceutical composition | |
| CN103585583A (en) | Traditional Chinese medicine composition for treating hepatic calculus and application thereof | |
| CN101979084B (en) | Chinese medicinal composition for warming kidney and tonifying yang and preparation method thereof | |
| CN106039194A (en) | Composite preparation for treating leucopenia caused by radiotherapy and chemotherapy | |
| CN1927260A (en) | Application of walnut oil in pharmaceutical preparation for preventing and treating osteoporosis | |
| CN106110178A (en) | A kind of for compound medicine treating cerebral infarction and preparation method thereof | |
| CN103784881B (en) | A kind of Chinese medicine composition and preparation method thereof for treating dysmenorrhoea | |
| CN104435149A (en) | Traditional Chinese medicine composition containing kadsura pepper stem for treating gout | |
| CN104147268A (en) | Traditional Chinese medicine composition and preparation thereof for treating hepatic and gallbladder calculus | |
| CN104306708A (en) | Medicine for treating spleen deficiency type menstrual period irregularity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Xinchun Inventor after: Zhao Zhijun Inventor after: Han Dazheng Inventor after: Chen Jingtao Inventor after: Liu Zhigang Inventor after: Duan Ying Inventor before: Wang Xinchun Inventor before: Zhao Zhijun Inventor before: Han Dazheng Inventor before: Chen Jingtao Inventor before: Liu Zhigang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG XINCHUN ZHAO ZHIJUN HAN DAZHENG CHEN JINGTAO LIU ZHIGANG TO: WANG XINCHUN ZHAO ZHIJUN HAN DAZHENG CHEN JINGTAO LIU ZHIGANG DUAN YING |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 Termination date: 20120826 |